Day One Biopharmaceuticals Management
Management criteria checks 3/4
Day One Biopharmaceuticals' CEO is Jeremy Bender, appointed in Sep 2020, has a tenure of 4.25 years. total yearly compensation is $6.91M, comprised of 9.4% salary and 90.6% bonuses, including company stock and options. directly owns 1.7% of the company’s shares, worth $21.96M. The average tenure of the management team and the board of directors is 3.3 years and 3.8 years respectively.
Key information
Jeremy Bender
Chief executive officer
US$6.9m
Total compensation
| CEO salary percentage | 9.4% |
| CEO tenure | 4.3yrs |
| CEO ownership | 1.7% |
| Management average tenure | 3.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Nov 04
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$84m |
| Jun 30 2024 | n/a | n/a | -US$167m |
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$7m | US$647k | -US$189m |
| Sep 30 2023 | n/a | n/a | -US$175m |
| Jun 30 2023 | n/a | n/a | -US$166m |
| Mar 31 2023 | n/a | n/a | -US$157m |
| Dec 31 2022 | US$5m | US$610k | -US$142m |
| Sep 30 2022 | n/a | n/a | -US$124m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$183m |
| Dec 31 2021 | US$20m | US$523k | -US$171m |
| Sep 30 2021 | n/a | n/a | -US$183m |
| Jun 30 2021 | n/a | n/a | -US$167m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$3m | US$142k | -US$41m |
Compensation vs Market: Jeremy's total compensation ($USD6.91M) is about average for companies of similar size in the US market ($USD5.54M).
Compensation vs Earnings: Jeremy's compensation has increased whilst the company is unprofitable.
CEO
Jeremy Bender (53 yo)
4.3yrs
Tenure
US$6,913,959
Compensation
Dr. Jeremy Bender, Ph D., M.B.A. serves as Chief Executive Officer, President and Director of Day One Biopharmaceuticals, Inc. since September 2020. He serves as President, Chief Executive Officer and Dire...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.3yrs | US$6.91m | 1.7% $ 22.0m | |
| Co-Founder and Head of R&D | 6.9yrs | US$2.49m | 2.02% $ 26.0m | |
| COO, CFO & Secretary | 3.8yrs | US$3.55m | 0.24% $ 3.1m | |
| General Counsel and Chief Compliance Officer | 2.2yrs | US$2.77m | 0.032% $ 411.3k | |
| Chief Technology Officer | no data | no data | no data | |
| Chief People Officer | 3.3yrs | no data | no data | |
| Chief Development Officer | no data | no data | no data | |
| Chief Commercial Officer | 1.9yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
3.3yrs
Average Tenure
53yo
Average Age
Experienced Management: DAWN's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.3yrs | US$6.91m | 1.7% $ 22.0m | |
| Independent Director | 4.3yrs | US$350.75k | 0.072% $ 924.7k | |
| Board Observer | no data | no data | no data | |
| Chairman of the Board & Lead Independent Director | 2.3yrs | US$383.38k | 0% $ 0 | |
| Board Observer | no data | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 3.3yrs | US$342.88k | 0% $ 0 | |
| Independent Director | 5yrs | US$342.88k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$351.75k | 0.040% $ 517.9k | |
| Independent Director | 3.8yrs | US$352.50k | 0.057% $ 733.0k | |
| Independent Director | less than a year | no data | 0% $ 0 |
3.8yrs
Average Tenure
55yo
Average Age
Experienced Board: DAWN's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 22:30 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Day One Biopharmaceuticals, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Naureen Quibria | Capital One Securities, Inc. |
| Andrea Newkirk | Goldman Sachs |